Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer.
Brassard M, Neraud B, Trabado S, Salenave S, Brailly-Tabard S, Borget I, Baudin E, Leboulleux S, Chanson P, Schlumberger M, Young J.
Brassard M, et al. Among authors: baudin e.
J Clin Endocrinol Metab. 2011 Sep;96(9):2741-9. doi: 10.1210/jc.2010-2771. Epub 2011 Jun 29.
J Clin Endocrinol Metab. 2011.
PMID: 21715537
Clinical Trial.